CMI: One powerful means of immune protection against virus infection is mediated by T cells in the body. This is called Cell-Mediated Immune (CMI) responses through triggering antigen-specific T cells that elminate infected cells in the system. CRV-101 is a next-generation vaccine designed to maximize the CMI protection by combining the gE protein antigen with our proprietary adjuvant. This strategy contrasts to the traditional approach using live attenuated virus.

The Varicella-Zoster Virus (VZV)

  • Infection with VZV causes two clinically distinct diseases. Primary infection with VZV results in Varicella (chickenpox) and the reactivation of VZV later in life results in Herpes Zoster (Shingles) and Post-Herpetic Neuralgia (PHP)
  • Varicella (chickenpox) is characterized by vesicular lesions on an erythematous base in different stages of development; lesions are most concentrated on the face and trunk.
  • Herpes Zoster (shingles) results from reactivation of latent VZV that gained access to sensory ganglia during varicella. Herpes zoster is characterized by a painful, unilateral vesicular eruption, which usually occurs in a restricted dermatomal distribution.


  • An effective VZV vaccine requires potent induction of VZV-specific cell-mediated immunity(CMI) since reduced CMI to VZV has been associated with increased risks of  developing shingles
  • Preclinical data shows CRV-101 induces long-lived VZV specific T cell responses.
  • CRV-101-100, Curevo’s current Phase I first-in-human study, shows encouraging preliminary safety and tolerability results. Interim trial results demonstrating a promising safety and tolerability profile of the vaccine in 90 healthy adults ≥18 to <50 years show that the vaccine is extremely safe and well tolerated with no Grade 3 or Grade 4 local reactogenicity.